Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-ALA in adult ATR-X syndrome with mild to moderate intellectual disability
jRCTs041250198Recruiting
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of 5-aminolevulinic acid in Alpha thalassemia X-linked intellectual disability syndrome (ATRX) and intellectual disability (ID). Started Mar 2026; status: recruiting.
02
Drugs
5-aminolevulinic acid
03
Conditions
Alpha thalassemia X-linked intellectual disability syndrome (ATRX)intellectual disability (ID)
Beyond the preview
Go deeper on jRCTs041250198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041250198.